Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (10)	4/5/2001 7:41:31 AM
From: nigel bates	Read Replies (1) \| Respond to of 1840

April 5, 2001--ImClone Systems Incorporated (Nasdaq: IMCL - news) announced today that the Company has received U.S. Patent No. 6,217,866 from the United States Patent and Trademark Office covering the therapeutic combination of anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibodies and anti-neoplastic agents, such as chemotherapeutic agents, for use in the treatment of cancer. IMC-C225, an investigational monoclonal antibody, is designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of cancer cells. The patent covers a composition of matter of any EGFR monoclonal antibody that inhibits the binding of EGF to its receptor, in combination with any anti-neoplastic agent, as well as the therapeutic use of such combinations. ``Combination therapy has become the gold standard in the treatment of patients with cancer,'' stated Samuel D. Waksal, Ph.D., President and Chief Executive Officer of ImClone Systems Incorporated. ``This patent will protect ImClone Systems from commercialization by competitive programs of any anti-EGFR monoclonal antibodies for use with chemotherapy in the treatment of cancer.''...

To: Miljenko Zuanic who wrote (10)	4/5/2001 12:25:56 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 1840

Miljenko: >>I do not believe to much in C225, but that is another story<< Wilder: If not having heart attack, at least needing oxygen. Miljenko, I hate to ask for your time and I never expect it, but I love stories...even short ones with unhappy endings. --Wilder